About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 159 record(s)
Req # A-2019-001009
Adverse Drug Reactions (ADRs) for Chlorhexidine. Report numbers: 000725334, 000725411, 000725428, 000725434, 000725439, 000725442, 000725446, 000725500, 000725506, E2B_02466826, E2B_02467708, E2B_02467710, E2B_02469532, E2B_02479840, 000725624, 000725643, 000725711, 000725770, 000725821, 000725822, 000725824, E2B_02535786. ADRs for Nicotine. Report numbers: 000723298, E2B_02446830, E2B_02456263, E2B_02478261, E2B_02478354, E2B_02487552, E2B_02491357,E2B_02494777, E2B_02508747, E2B_02532088.Organization: Health Canada
September 2022
Req # A-2019-001729
Adverse Drug Reactions (ADRs) for immunoglobulin (human). Report numbers: 000729698, 000729737, 000729753, E2B_02721074, E2B_02725284, E2B_02745409, E2B_02745430, E2B_02757454, E2B_02757460, E2B_02757483, E2B_02758498, E2B_02758510, E2B_02761164, E2B_02761166, E2B_02762212, E2B_02770935, E2B_02790551, E2B_02790674, E2B_02791333, E2B_02806975.Organization: Health Canada
September 2022
Req # A-2020-000935
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-109891-294.Organization: Health Canada
September 2022
Req # A-2020-001118
Adverse Drug Reactions (ADRs). Report numbers: E2B_02194141, E2B_02194231, E2B_02196619, E2B_02196705, E2B_02196717, E2B_02199201, E2B_02199223, E2B_02199231, E2B_02199293, E2B_02199808, E2B_02200059, E2B_02201762, E2B_02202036, E2B_02202050, E2B_02202243, E2B_02202438, E2B_02202454, E2B_02202528, E2B_02203600, E2B_02204012.Organization: Health Canada
September 2022
Req # A-2020-001145
Adverse Drug Reactions (ADRs). Report numbers: E2B_02321406, E2B_02321840, E2B_02323070, E2B_02323093, E2B_02323110, E2B_02323596, E2B_02323621, E2B_02324669, E2B_02325522, E2B_02326954, E2B_02326990, E2B_02327172, E2B_02328369, E2B_02328379, E2B_02328380, E2B_02328405, E2B_02328424, E2B_02328614, E2B_02329080, E2B_02329268.Organization: Health Canada
September 2022
Req # A-2020-001184
Adverse Drug Reactions (ADRs). Report numbers: E2B_02424240, E2B_02424378, E2B_02424435, E2B_02424630, E2B_02425161, E2B_02425170, E2B_02425179, E2B_02427052, E2B_02427055, E2B_02427212, E2B_02427224, E2B_02427228, E2B_02427229, E2B_02427233, E2B_2427312, E2B_02427435, E2B_02428405, E2B_02428423, E2B_02428753, E2B_02429833.Organization: Health Canada
September 2022
Req # A-2020-001345
Adverse Drug Reactions (ADRs). Report numbers: E2B_02079242, E2B_02086576, E2B_02087040, E2B_02207354, E2B_02218589, E2B_02247236, E2B_02251088, E2B_02271649, E2B_02274332, E2B_02285866, E2B_02290975, E2B_02297390, E2B_02297391.Organization: Health Canada
September 2022
Req # A-2020-001476
Adverse Drug Reactions (ADRs) for Leflunomide. Report numbers: E2B_03053730 E2B_03053961 E2B_03054156 E2B_03054221 E2B_03054792 E2B_03056438 E2B_03057658 E2B_03070808 E2B_03070831 E2B_03071119 E2B_03073676 E2B_03068903 E2B_03075214 E2B_03075702 E2B_03075712 E2B_03076259 E2B_03081220 E2B_03081611 E2B_03081624 E2B_03081657.Organization: Health Canada
September 2022
Req # A-2020-001716
Adverse Drug Reactions (ADRs). Report numbers: E2B_02817171, E2B_02817204, E2B_02817208, E2B_02817395, E2B_02817477, E2B_02817487, E2B_02817496, E2B_02817508, E2B_02817516, E2B_02817597, E2B_02817606, E2B_02817842, E2B_02818188, E2B_02818364, E2B_02821203, E2B_02833832, E2B_02859664, E2B_02870466, E2B_02878282, E2B_02891039.Organization: Health Canada
September 2022
Req # A-2020-001724
Adverse Drug Reactions (ADRs). Report numbers: E2B_02909836, E2B_02912336.Organization: Health Canada
September 2022